Demographic and baseline characteristics
| Characteristic . | No. . | % . |
|---|---|---|
| Gender | ||
| Male | 30 | 88 |
| Female | 4 | 12 |
| Race | ||
| White | 22 | 65 |
| African American | 5 | 15 |
| Hawaiian/Pacific Islander | 1 | 3 |
| Asian | 2 | 6 |
| Unknown | 4 | 12 |
| Ethnicity | ||
| Hispanic | 8 | 24 |
| Non-Hispanic | 26 | 76 |
| Age, years | ||
| Median | 42.0 | |
| Range | 19-55 | |
| CDC risk group | ||
| Homosexual/bisexual contact | 14 | 41 |
| Heterosexual contact | 10 | 29 |
| IVDU | 3 | 9 |
| Heterosexual contact and IVDU | 1 | 3 |
| Homosexual/bisexual and heterosexual contact | 3 | 9 |
| Other (needle sticks, congenital HIV, unknown) | 3 | 9 |
| Receiving HAART at diagnosis | 26 | 76 |
| Absolute CD4 count (n = 33) | ||
| Median | 195.0 | |
| SD | 174.6 | |
| Min-max | 0-721 | |
| HIV load (n = 33) | ||
| Median | 1819 | |
| Min-max | Undetectable-1 187 968 | |
| Ann Arbor stage | ||
| I | 4 | 12 |
| II | 2 | 6 |
| IIE | 1 | 3 |
| III | 2 | 6 |
| IV | 25 | 74 |
| Karnofsky performance status | ||
| 40%-60% | 7 | 23 |
| >70% | 26 | 77 |
| Local pathology diagnosis (n = 35) | ||
| BL | 33 | 97 |
| Burkitt-like lymphoma | 1 | 3 |
| Central pathology diagnosis (n = 25) | ||
| BL | 17 | 71 |
| High-grade, unclassifiable B-cell lymphoma with features intermediate between DLBCL and atypical BL | 3 | 21 |
| Indeterminate between DLBCL and BL | 1 | 7 |
| DLBCL | 3 | 6 |
| High-grade NHL, not otherwise specified | 1 | 7 |
| Characteristic . | No. . | % . |
|---|---|---|
| Gender | ||
| Male | 30 | 88 |
| Female | 4 | 12 |
| Race | ||
| White | 22 | 65 |
| African American | 5 | 15 |
| Hawaiian/Pacific Islander | 1 | 3 |
| Asian | 2 | 6 |
| Unknown | 4 | 12 |
| Ethnicity | ||
| Hispanic | 8 | 24 |
| Non-Hispanic | 26 | 76 |
| Age, years | ||
| Median | 42.0 | |
| Range | 19-55 | |
| CDC risk group | ||
| Homosexual/bisexual contact | 14 | 41 |
| Heterosexual contact | 10 | 29 |
| IVDU | 3 | 9 |
| Heterosexual contact and IVDU | 1 | 3 |
| Homosexual/bisexual and heterosexual contact | 3 | 9 |
| Other (needle sticks, congenital HIV, unknown) | 3 | 9 |
| Receiving HAART at diagnosis | 26 | 76 |
| Absolute CD4 count (n = 33) | ||
| Median | 195.0 | |
| SD | 174.6 | |
| Min-max | 0-721 | |
| HIV load (n = 33) | ||
| Median | 1819 | |
| Min-max | Undetectable-1 187 968 | |
| Ann Arbor stage | ||
| I | 4 | 12 |
| II | 2 | 6 |
| IIE | 1 | 3 |
| III | 2 | 6 |
| IV | 25 | 74 |
| Karnofsky performance status | ||
| 40%-60% | 7 | 23 |
| >70% | 26 | 77 |
| Local pathology diagnosis (n = 35) | ||
| BL | 33 | 97 |
| Burkitt-like lymphoma | 1 | 3 |
| Central pathology diagnosis (n = 25) | ||
| BL | 17 | 71 |
| High-grade, unclassifiable B-cell lymphoma with features intermediate between DLBCL and atypical BL | 3 | 21 |
| Indeterminate between DLBCL and BL | 1 | 7 |
| DLBCL | 3 | 6 |
| High-grade NHL, not otherwise specified | 1 | 7 |
CDC, Centers for Disease Control and Prevention; IVDU, intravenous drug user; SD, standard deviation.